South Korea · Research startup
South Korea · G+FLAS Life Sciences, Inc.
G+FLAS Life sciences has been developing CRISPR/Cas foundation technologies as well as innovative applications for better human health, including gene therapy drugs, biopharmaceuti
Funding reportedLast round: Series E
About G+FLAS Life Sciences, Inc.
G+FLAS Life sciences has been developing CRISPR/Cas foundation technologies as well as innovative applications for better human health, including gene therapy drugs, biopharmaceuti
cals, and novel seeds with desired traits.
What company datasets say G+FLAS Life Sciences, Inc. raised
Funding, as reported
On 2 portfolio pages
Investors who name them
Each firm lists G+FLAS Life Sciences, Inc. on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
The company, in detail
What they build
Known for
crispr-casnhealth carecrispr mechanismsbiotechnology researchdistributionmanufacturingcrispr productscrispr applicationsgmp manufacturingdnafree genome editingcrispr non-gmonon-gmo editinggfcas12agenome editinghospital & health carecrispr enzyme
Built with from their website
Google Tag ManagerNAVEROpenSSLApacheYouTubeCloudFlareViewport MetaCentOSMicrosoft ExchangeMicrosoft 365 Apps & Services
+8 more
Mobile FriendlyOpen GraphjQueryEditPlusGoogle AnalyticsNaver AnalyticsGoDaddy DomainsMicrosoft Exchange Online
- Sector
- Research
- Industry code
- NAICS 541714, 325414, SIC 8731
- Region
- Seoul
- Full record
- Every detail in the company directory
Research in South Korea
Startups like it
Is this your company?
Add your raise, your deck and your story, and put G+FLAS Life Sciences, Inc. in front of investors. Or tell us what we have wrong.